Current Role of Biological Agents in Colorectal Cancer
Hong Kong J Radiol 2010;13(Suppl):S3-9
J Cassidy
Colorectal cancer is one of the most frequently diagnosed malignancies in the world. In spite of recent advances in chemotherapy, the prognosis for patients with metastatic colorectal cancer remains poor. The last decade of ground-breaking research on molecular pathways involved in tumour growth has paved the way for targeted therapies, such as bevacizumab and cetuximab. Emerging data contribute to our understanding of the clinical application of these novel therapies in the pharmaceutical armamentarium for colorectal cancer. The identification of biomarkers associated with disease control, including K-ras and B-raf mutations, is changing the colorectal cancer treatment paradigm. Clinical and molecular predictive markers of response are being evaluated. Recent clinical studies may help us better select patients who could benefit from targeted therapies, and thus optimise patient outcomes and minimise unnecessary toxicities.
中文摘要
治療結直腸癌的最新生物製劑發展
J Cassidy
結直腸癌是最常見的癌症之一。儘管化療技術有最新發展，轉移性結直腸癌的預後仍然很差。過去 十年，對腫瘤生長的分子路徑的研究有突破性進展，為標靶治療（如阿瓦斯汀bevacizumab及西妥昔 單抗cetuximab）打下了基礎。最新的數據更有助我們了解這些在治療結直腸癌藥物庫中的嶄新療法 於臨床上的使用。辨析與病情控制有關的生物標記，包括K-ras及B-raf基因突變，正在改變結直腸癌 的治療模式。研究人員現正評估可預測療效的臨床及分子指標。最新的臨床研究有助我們更好的篩 選那些可受惠於標靶治療的病人，從而確保病人得到最佳的臨床效果及減少不必要的治療毒性。